Ultrasound (US) is an effective tool for local delivery of genes into target tumors or organs. In combination with microbubbles, US can temporarily change the permeability of cell membranes by cavitation and facilitate entry of plasmid DNA into cells. Here, we demonstrate that repeated US-mediated delivery of anti-angiogenic genes, endostatin or calreticulin, into muscle significantly inhibits the growth of orthotopic tumors in the liver, brain or lung. US-mediated anti-angiogenic gene therapy also seems to function as an adjuvant therapy that significantly enhances the antitumor effects of the chemotherapeutic drug doxorubicin and adenovirus-mediated cytokine gene therapy. Significantly higher levels of tumor apoptosis or tumor-infiltrating lymphocytes were observed after combined therapy consisting of either anti-angiogenic therapy and chemotherapy, or anti-angiogenic therapy and immunotherapy. Taken together, our experiments demonstrate that intramuscular delivery of anti-angiogenic genes by US exposure can effectively treat distant orthotopic tumors, and thus has great therapeutic potential in terms of clinical treatment.
Introduction
Ultrasound (US) is a newly developed non-viral approach for delivering genes into cells or tissue.
1,2 US exposure can induce temporary micropores in the membrane of target cells through which DNA molecules can pass. This phenomenon is referred to as 'sonoporation'. The cell membrane damage is repaired soon after US exposure ends and the DNA is then trapped in the cells. 3 The mechanisms associated with US-mediated gene transfer into cells are not fully understood, but the cavitation activity produced by US is believed to have a pivotal role in the increase in cell membrane permeability. 4 Cavitation is the formation and oscillation of small gas-filled bubbles in a US-exposed medium. 5 Moreover, several studies have reported that the transfection efficiency of sonoporation is greatly enhanced by use of echo-contrast agents, 6, 7 namely gas-filled microbubbles, which serve as cavitation nuclei 8, 9 and significantly decrease the threshold needed for acoustic cavitation to occur under US. 10 In vivo sonoporation has been used to successfully deliver DNA into many different tissues types, including cardiac tissue, 11, 12 the vasculature, 7, 13 kidney, 14 liver, 6 ,15 skeletal muscle [16] [17] [18] and tumors. 11, 19, 20 Local expression of a gene is achieved in these tissues. In addition, systemic expression of human growth hormone or interleukin (IL)-12 has been seen to occur when the gene is delivered to skeletal muscle through US. These secretory proteins are then delivered to the target tissues or tumors through blood circulation. 18, 21 Skeletal muscle, which constitutes about 30% of adult body mass and has an abundant blood vascular supply, lends itself as a target tissue for production of transgene proteins that can act as systemic therapeutic agents. [16] [17] [18] In this regard, producing anti-angiogenic factors for treatment of cancer would be of great interest.
Tumors above a critical size use angiogenesis to obtain oxygen, nutrients and growth factors, as well as for removing catabolites, thus allowing them to grow unchecked. 22 Angiogenesis therefore is considered to be a promising target in the treatment of cancers. 23, 24 In targeting angiogenesis inhibition, gene therapy-based strategies provide potential advantages over conventional modalities for administering anti-angiogenic drugs. First, sustained treatment may be required for effective suppression of pathological angiogenesis (for example, in cancer), and gene therapy strategies are more conducive to achieving prolonged expression of the therapeutic proteins than administration of an anti-angiogenic protein, particularly if the protein has a short half-life. Second, gene therapy strategies can circumvent the production problems associated with many recombinant proteins, such as solubility, stability and protein modification. Third, in vivo gene expression allows proteins to be assembled in a physiological environment, potentially resulting in more stable and active proteins.
Recently, Duvshani-Eshet et al. 25 published promising antitumor results from using US-mediated transduction to target anti-angiogenic gene expression toward tumors. However, given the difficulty of accessing many orthotopic or metastatic tumors, delivering genes to muscle tissue and letting the therapeutic proteins function systemically may be more advantageous. In this context, our previous study demonstrates that US-mediated gene delivery is more effective in muscle tissue than in tumors. 26 The goal of the current study is to test the therapeutic effect of US-mediated intramuscular expression of anti-angiogenic genes on distant orthotopic tumors. Our results show that repeated US administration to deliver endostatin (ED) or calreticulin (CRT) genes to muscle led to a significant antitumor effect on distant orthotopic tumors in the liver, brain or lungs. This US-mediated therapy could be further combined with chemotherapy or immunotherapy to yield enhanced and prolonged antitumor effects.
Materials and methods

Preparation of plasmids
This study used an expression plasmid encoding an enhanced green fluorescence protein (EGFP), a mouse ED linked to a signal peptide (MAAGPRTSVLLAFALL CLPWTQEV) derived from porcine growth hormone or a rabbit CRT (provided by Dr TC Wu at Johns Hopkins University). The expression of these cDNAs was obtained under the control of a cytomegalovirus immediate early gene promoter. All the plasmids for in vivo injection were amplified and purified using the Giga Kit, QIAGEN EndoFree (Qiagen, Valencia, CA).
Cell lines BNL is a cell line derived from chemically transformed hepatic epithelial cells in a BALB/c mouse; LL/2 is a murine Lewis lung adenocarcinoma cell line; and RT-2 is a rat glioma cell line. HEK293 is a human embryonic kidney cell line used for adenovirus (Ad) production. The cell lines were maintained in Dulbecco's modified Eagle's medium (Seromed, Berlin, Germany) supplemented with 10% fetal calf serum (Biological Industries, BeitHaemek, Israel), 2 mM L-glutamine, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin. All cells were cultured at 37 1C in a 5% CO 2 incubator.
Construction of adenoviral vectors
As described previously, an adenoviral vector was constructed containing either a mouse granulocytemacrophage colony-stimulating factor (GM-CSF) cDNA, a mouse single-chain IL-12 gene or an EGFP gene, all under the control of a cytomegalovirus immediate early gene promoter. 27, 28 The Ads were all amplified in HEK293 cells and purified using AdEasy Virus Purification Kits (Stratagene, Santa Clara, CA) following the manufacturer's instructions.
US treatments
The SonoVue echo-contrast agent (Bracco, Milan, Italy) was first reconstituted in phosphate-buffered saline (PBS) for a concentration of 2B5 Â 10 8 microbubbles per ml. Plasmid DNA (100 mg for mice or 200 mg for rats) was then mixed with 30% (v/v) of the microbubble echocontrast agent to yield a total volume of 30 ml. The DNA/ SonoVue mixture solution was injected into the muscle of each test animal followed by US exposure using a Sonitron 2000 sonoporation device (Rich-Mar, Inola, OK). US was generated by a 1-MHz therapeutic US probe with an average intensity of 0.4 W cm
À2
, a duty cycle of 20% and a pulse repetition frequency of 200 Hz.
Animal experiments
All experimental protocols were performed under the guidelines set by the Animal Care and Use Committee of National Taiwan University College of Medicine. During operations, animals were anesthetized with an intraperitoneal injection of ketamine and xylazine, and killed by CO 2 asphyxiation.
Generation and treatment of s.c. tumors. Male BALB/c mice (6 weeks old) were each subcutaneously inoculated in the flank with 5 Â 10 5 BNL cells. When the tumors reached about 100 mm 3 (B2 weeks), the animals were randomly divided into several groups (n ¼ 6 for each group) and treated with US using either the intermittent protocol or the consecutive protocol. In the intermittent protocol, intramuscular injection of plasmid DNA solution and US exposure were conducted four times at 7-day intervals over 28 days. For the consecutive protocol, the entire procedure was repeated every day for four consecutive days. Tumor volumes were calculated every 3 days by measuring the diameter of each tumor with calipers, using the formula V ¼ (a Â b 2 ) Â 0.52, where V is the volume, a is the larger diameter and b is the smaller diameter. Tumor progression was followed over 28 days.
Generation and treatment of orthotopic liver tumors. The mouse orthotopic liver tumor model was established by implanting 3 Â 10 5 BNL cells in the liver by a process described previously. 29 Beginning 7 days later, the animals were then treated four times by US and DNA at 7-day intervals. The animals were killed on day 35 and tumor volumes were measured. A parallel set of experiments was conducted in a similar manner but the animals were kept alive; treatments for this group were terminated after four US treatments and the long-term survival rates of the animals were analyzed. The primary multifocal liver tumor model was established in rats by feeding the animals with diethylnitrosamine following a previously described protocol. 30 The tumor model is harder to treat than the implanted model, so the animals were treated by US four times at 3-day intervals and killed on day 14 so tumor volumes could be measured following a previously described method. 30 For the combined chemotherapy and US treatment experiments, animals received US therapy on days 14, 21, 28 and 35 after tumor inoculation. Doxorubicin (DOX) (2.5 mg kg À1 ) was administered intraperitoneally on days 15 and 29. Tumor volumes were measured on day 40 using calipers. For the combined immunotherapy and US treatment experiments, animals first received a single injection of 30 ml of Ads (0.5 Â 10 9 Ad/GM-CSF þ 0.5 Â 10 9 Ad/IL-12 (that is, G þ I) or 1 Â 10 9 Ad/LacZ) or 30 ml of PBS intra-tumorally on 14 days after tumor implantation. Seven days later, they received the first of three US treatments at 7-day intervals. Tumor volumes were measured using calipers 5 days after the last US treatment.
Generation and treatment of orthotopic brain tumors. Intra-cerebral tumors were established by implanting RT-2 cells in the brains of 8-week-old Fischer 344 rats as described previously. 31 After tumor implantation, animals were randomly divided into four groups (n ¼ 6 for each group). One day later, the animals received the first of five US treatments administered every other day. The tumors were harvested and the sizes were determined using calipers 12 days after tumor implantation.
Generation and treatment of orthotopic lung tumors. The lung tumor model was established by injecting LL/2 cells (3 Â 10 5 per mouse) into the tail vein of 8-week-old C57BL/6J mice. After tumor cell injection, the mice were randomly divided into four groups (n ¼ 6 for each group). One day later, the animals received the first of five US treatments administered every other day. Twelve days after tumor injection the mice were killed and their lungs were analyzed for tumor colonization. 32 The lungs were rinsed with PBS and then placed in a beaker containing Bouin's solution. After 24 h, the lungs were rinsed in water to remove excess Bouin's solution and the tumor colonies were counted under a dissecting microscope.
IHC staining and TUNEL assays
Tumor tissues were removed from animals and analyzed by immunohistochemical (IHC) staining as described previously. 30 The sections were stained with a rat anti-mouse CD4, CD8 or CD31 monoclonal antibody (all at 1:50 dilution; BD Biosciences Pharmingen, Franklin Lakes, CA). Apoptotic cells were detected by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay using an in situ detection kit (Roche, Mannheim, Germany) following the manufacturer's instructions.
Analysis of transgene expression by RT-PCR
RNA was extracted from the DNA-injected muscle using the Trizol reagent (Invitrogen, Carlsbad, CA). One microgram of the RNA was subjected to reverse transcription using Moloney murine leukemia virus reverse transcriptase with random primers. One-fiftieth of the cDNA product was amplified by PCR using the following primers: ED, GATTTCCAGTGCTTCCAGCAA and GCTATAGAGATCCTGCAGCCTAGAG; CRT, TCA TGTTTGGTCCTGACATCTGT and CGTTCTTGCCC TTGTAGTTGAA; and b-actin, GATCTGGCACCAC ACCTTCT and CTTTTCACGGTTGGCCTTAG. The reaction mixture was denatured at 95 1C for 3 min, followed by PCR with 35 cycles for ED, 25 cycles for CRT and 28 cycles for b-actin 95 1C for 30 s and 72 1C for 20 s.
Statistical analysis
All data are expressed as means ± s.d. Survival analysis was performed using the Kaplan-Meier survival curve and analyzed by log-rank test, whereas the rest of the data in this study were analyzed by Mann-Whitney U-test. Differences were considered statistically significant when Po0.05.
Results
An intermittent treatment protocol for s.c. tumors is better than a consecutive treatment protocol At the beginning of this study it was not clear whether the anti-angiogenic factors worked better when administered intermittently while the tumor was growing or when administered intensively during the initial stage of tumor growth. Therefore, we designed two US treatment protocols to deliver the ED or CRT gene into muscle tissue to treat a s.c. tumor model. The BNL tumor cells were implanted in the animals' flanks until tumors were palpable (B2 weeks). The animals were then intramuscularly injected with PBS, EGFP DNA, ED DNA or CRT Wistar rats with diethylnitrosamineinduced multifocal liver tumors were treated with the indicated US therapies using the protocol shown at the top of the figure. On day 14 after treatment, tumor volumes were measured as described previously. 30 In panels a and c, the numbers above the bars indicate the percentages of the average tumor volumes relative to those of the PBS control (n ¼ 6 for each group). For statistical difference in tumor volumes, *Po0.05; ***Po0.001, Mann-Whitney U-test, as compared between the indicated groups. CRT, calreticulin; ED, endostatin; EGFP, enhanced green fluorescence protein; PBS, phosphate-buffered saline; US, ultrasound.
DNA mixed with SonoVue, an echo-contrast agent, and then exposed to US. The consecutive protocol was performed by repeating the entire procedure daily over the initial four consecutive days (Figure 1a) , whereas the intermittent protocol was performed by repeating the procedure once a week over 4 weeks (Figure 1b) . Tumor volumes were measured every 3 days. As the results show, tumor growth suppression with both the US-mediated ED (US/ED) and US-mediated CRT (US/CRT) treatments was significantly greater than with the PBS or EGFP control treatments using both treatment protocols (Figures 1a and b) . On day 28, for the consecutive treatment, the respective average tumor weights were 44% and 57% in the US/ED and US/CRT groups, relative to those in the PBS group. When the intermittent treatment was used, the respective average tumor weights were only 26% and 43% in the US/ED and US/CRT groups (Figure 1c) . These results indicate that the intermittent protocol is much more effective than the consecutive protocol (Po0.01 between two protocols for both genes). In addition, ED seemed to slightly outperform CRT on the s.c. tumors (Po0.05 by the consecutive protocol and Po0.01 by the intermittent protocol). Notably, compared with the PBS control treatment, neither US exposure alone nor solely intermittent DNA injection without US exposure showed discernible therapeutic effects (Supplementary Figure S1 ), suggesting that the antitumor effects resulted from the US-mediated ED or CRT gene transfer. Transgene expression in the injected site was confirmed by reverse transcription-PCR. Significantly elevated expression of ED and CRT was respectively observed in the muscles of animals treated with US/ED and US/CRT 3 days after the first US treatment (Figure 1d ), albeit against a highly endogenous background.
Intramuscular US/ED or US/CRT therapy effectively regresses distant orthotopic liver tumors
As intramuscular delivery of the ED or CRT gene worked for s.c. tumors, we next investigated whether the same strategy would work for distant orthotopic tumors. In the first group of experiments, BNL hepatoma cells were inoculated into the livers of BALB/c mice to form orthotopic liver tumors. Seven days later, the mice were treated with US therapy in the muscle once a week over 4 weeks. Tumor volumes were then measured 35 days after tumor implantation. Results showed that both the US/ED and US/CRT treatments respectively reduced tumor volumes to 37% and 43% the size of those in the PBS control group (Po0.001; Figure 2a ). The survival curves for the mice receiving the US therapies are shown in Figure 2b . The respective life spans of the animals receiving US/ED or US/CRT was 72 and 63 days, a significant improvement over the 38 and 40 days of the PBS or US/EGFP control group. Intermittent US therapy was also shown to reduce liver tumor volume using an in vivo image system (Supplementary Figure S2) .
We further tested the approach on a rat primary liver tumor model. As described previously, feeding of diethylnitrosamine into rats induces multifocal tumor nodules in the liver. 30 This tumor model is more difficult to treat than the implanted tumor model, so animals thus treated were administered four sessions of US therapy at 3-day intervals. The results presented in Figure 2c reveal that the US/ED and US/CRT therapies respectively reduced the tumor volumes to 26% and 32% the size of those of the PBS control. It is worth noting that, in this liver tumor model, ED and CRT functioned comparably well.
Intramuscular US/ED or US/CRT therapy effectively regresses orthotopic brain and lung tumors US-mediated intramuscular therapy was also applied to other types of orthotopic tumors. In the first example, RT-2 glioma cells were implanted intra-cerebrally in Fischer 344 rats to form orthotopic brain tumors.
In the second example, LL/2 lung adenocarcinoma cells were intravenously injected into C57BL/6J mice to form multifocal lung tumors. In both models the tumors are highly malignant and the tumor-bearing animals usually die in 2 weeks. In this context, the intermittent US therapy protocol was performed every other day for 5 days from the day after tumor cell implantation (Figure 3a) . Encouragingly, both the orthotopic brain tumors (Figure 3b ) and the lung tumors ( Figure 3c) were significantly regressed by US/ED or US/CRT treatment. Collectively, these results indicate that repeated delivery of ED or CRT gene into muscle by US exposure provides significant systemic therapeutic effects by inhibiting the growth of distant orthotopic tumors, such as those in the liver, brain and lung.
Intramuscular US/ED or US/CRT therapy can enhance the antitumor effects of DOX We next tested whether repeated US/ED or US/CRT treatment could enhance the antitumor activity of chemotherapeutic drugs when treating large tumors. Mice bearing 14-day-old orthotopic liver tumors were treated with US therapy once a week over 4 weeks. In addition, they received DOX (2.5 mg kg 
Intramuscular US/ED or US/CRT therapy can synergize the therapeutic effects of immunotherapy
We have demonstrated previously that Ad-mediated cytokine gene therapy combined with GM-CSF and IL-12 produces antitumor effects superior to either cytokine monotherapy. 29 Even so, the combined immunotherapy shrinks large tumors (that is, 14 days) by only about 50%. 29 Thus, this study investigated whether repeated US/ED or US/CRT treatment could function as an adjuvant therapy to enhance and prolong the effects of Ad-mediated GM-CSF and IL-12 immunotherapy on large tumors. BALB/c mice were first intra-tumorally treated with PBS, Ad/LacZ or Ad/GM-CSF þ Ad/IL-12 (that is, G þ I) on day 14 after liver tumor implantation. Seven days later they received the first of 3 weekly US/ED or US/CRT treatments. Tumor volumes were measured 5 days after the final US treatment (Figure 5a) . The results showed that, whereas monotype therapy with either US/ED (that is, LacZ/ED) or G þ I (that is, G þ I/ EGFP) reduced respective tumor volumes to 52% and 56%, a combination of US/ED therapy and G þ I immunotherapy (that is, G þ I/ED) synergistically reduced tumor volume to 7% (Figure 5b, Po0.01) . A combination of US/CRT therapy and G þ I immunotherapy also significantly reduced tumor volume to 25% (Figure 5b) . The life span of mice treated with the G þ I/ED combination therapy was significantly prolonged to 90 days, as compared with 40 to 45 days for the PBS control group (Po0.001), or 75 days for the G þ I or the US/ED group (Figure 5c , Po0.05). Importantly, IHC staining revealed that the combination therapy group (G þ I/ED or G þ I/CRT) showed greater numbers of CD4 þ and CD8 þ T cells infiltrating in the tumors than did the single anti-angiogenic therapy group (LacZ/ED or Figures S4 and S5) . However, in comparison with the single-therapy groups, the combination therapy group showed a comparable or higher reduction of tumor vasculature (Figure 6c and Supplementary Figure S6) , and significantly enhanced tumor cell apoptosis (Figure 6d and Supplementary Figure S7 ) in the tumor region. Taken altogether, these results strongly suggest that Ad-mediated immunotherapy followed by repeated intramuscular US/ED or US/CRT treatment significantly enhances and prolongs the antitumor effects on large tumors.
Discussion
The present study is the first to apply the US technique to treat various distant orthotopic tumors in muscle tissue. US delivers genes into target tissues by changing the permeability of the cell membrane, allowing DNA to enter the targeted cells. The process is non-invasive and safe. Unlike viral vectors, US treatments can be repeated without inducing an immune response to the vector, which should greatly increase transduction efficiency and is helpful in treatment situations with specific conditions for duration and therapeutic protein levels.
Experimental results of US-mediated gene transfer into muscle produced several interesting findings. First, the anti-angiogenic therapy that targets muscle tissue is able to effectively reduce the volumes of various orthotopic tumors (Figures 2 and 3) . Many previous studies have successfully used recombinant anti-angiogenic proteins to treat tumors through s.c. 33, 34 or intravenous injection, 35, 36 indicating that anti-angiogenic proteins can function systemically. However, the half-lives of the anti-angiogenic proteins in circulation are usually short (for example, in vivo decay of endostatin is bi-exponential, resulting in a half-life (t 1/2 ) of 42.3 min and a b t 1/2 of 12.9 h), 37 which may result in disappointing therapeutic effects when used in clinical treatment. 33 On the other hand, DNA delivered into the muscle can be retained in the tissue for up to 1 week, 26 thus enabling the production of anti-angiogenic proteins over a longer period of time. The expression can be further sustained with repeated US treatments. In addition, the large area of skeletal muscle provides multiple site injections if higher amounts of the therapeutic proteins are needed. Second, our results showed that combining intramuscular anti-angiogenic therapy with chemotherapeutic drugs results in enhanced antitumor effects. Previous work has suggested that, after anti-angiogenic therapy, tumor vasculature may undergo morphological normalization, whereby immature and abnormal blood vessels are pruned, and the remaining vasculatures are remolded making them more like normal vasculature. 38 These improvements in tumor vasculature function may increase the transport efficiency of blood vessels, thus lowering the dose of chemotherapeutic drugs needed to achieve a significant antitumor effect. 39, 40 However, when we investigated this scenario, we found an additive rather than a synergistic antitumor effect (for example, 51% tumor reduction by DOX, 38% by ED and 81% by ED þ DOX) (Figure 4b ). This may be due to the presence of inappropriate levels of anti-angiogenic factors, as the window for vascular normalization-enhanced tumor drug delivery is transient. Excessive suppression of the tumor vasculature by uninterrupted anti-angiogenic treatment may prematurely close the normalization window and thus reduce the number of blood vessels. 41 To obtain synergistic antitumor effects, optimal dosing and scheduling of the anti-angiogenic therapy may be needed to enhance tumor drug delivery, and this should be investigated in depth in the future.
Third, we found that the antitumor activity of Ad-mediated immunotherapy was synergistically enhanced and prolonged by repeated intramuscular anti-angiogenic gene therapies. IHC staining showed that the levels of CD4 þ and CD8 þ T cells markedly increased when immunotherapy was combined with anti-angiogenic therapy. It is known that cytokine gene therapy can recruit macrophages and dendritic cells to tumor sites, where they engulf dead tumor cells or tumor antigens released from the dead cells, and this stimulates antitumor immune responses. The anti-angiogenic therapy thus augments the levels of tumor cell apoptosis, which leads to an enhanced antitumor immune response. Moreover, we also found recently that anti-angiogenic therapy may alleviate the immunosuppressive condition in large tumors, rendering tumor cells more susceptible to immunotherapy. 42 The therapeutic effects of using an adenoviral vector, although prominent, are usually transient owing to the immunogenic properties of the vector. The immunogenicity problems constrain the vector in terms of re-administration. Hence, US-mediated anti-angiogenic therapy can act as an adjuvant therapy and extend the therapeutic effects of Ad-mediated immunotherapy. Collectively, these phenomena may contribute to synergistic antitumor activity when USmediated anti-angiogenic therapy and immunotherapy are combined.
In conclusion, we have shown that US-mediated intramuscular delivery of anti-angiogenic genes is a promising strategy for treatment of orthotopic or metastatic tumors. It can also be used as an adjuvant therapy to augment or extend the therapeutic effects of existing therapeutic strategies. The expression levels of the genes delivered by US may not be as high as those transduced by viral vectors. However, owing to the non-immunogenic property of naked DNA, this method can be repeated multiple times. The method also offers greater convenience than preparation of viral vectors, so various DNAs can be delivered in different combinations more easily. In a nutshell, US-mediated gene transfer has great potentials for gene therapy of cancers.
